ClinicalTrials.gg
RecruitingNCT04836871Updated Jul 13, 2023

Double Filtration Plasmapheresis Combined With Chemotherapy

A Phase 1 interventional study of DFPP combined with chemotherapy in Multiple Myeloma, sponsored by Fuling Zhou. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-13.

Sponsored by Fuling Zhou · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
273rd of 406
20 · median 40
Started
2021
with 42 others
Phase 1
151 of 448
73 open now
Primary completion
2024-04
later than 13 of 274 live
Registered
138th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 273rd largest by planned enrollment of the 406 interventional ones that give a count, is one of 43 that started in 2021, is one of 151 in phase 1, reaches primary completion later than 13 of the 274 other live ones, and was the 138th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

Evaluation of double filtration plasmapheresis combined with chemotherapy for the treatment of abnormalities of M protein or renal function due to the multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Multiple myeloma patients who are diagnosed by bone marrow morphology and immunology
  • Patients with stable condition after conventional treatment
  • Patients with renal insufficiency or abnormal M protein
  • Patients over 18 years of age
  • Liver function: blood ≤ 35μmol/L, enzymes (AST)/aka alanine aminotransferase (ALT) is less than 2 times the
  • Normal heart function
  • Physical condition score 0-2 level ( score)
  • Obtain an form signed by the patient or family member

Exclusion criteria

Exclusion Criteria:

  • Allergies or obvious to any of the drugs involved in the plan
  • Severe heart disease, including myocardial infarction and cardiac insufficiency.
  • Suffering from other organ
  • Active tuberculosis patients and -positive patients
  • At the same time suffering from other blood system diseases
  • Pregnant or lactating women
  • Able to understand or follow the research plan
  • Past history of intolerance or allergy to similar drugs
  • Patients under 18 years of age
  • Participating in other clinical researchers at the same time
  • There are any other circumstances that hinder the progress of the research
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Double filtration plasmapheresis (DFPP) combined with chemotherapy

    Combination Product: DFPP combined with chemotherapy

Interventions

  • Combination productDFPP combined with chemotherapy

    Double filtration plasmapheresis combined with chemotherapy

06

What researchers measure

Primary outcomes

  1. M protein clearance rate

    before each treatment of Double filtration plasmapheresis (DFPP)

    Time frame: 1hour

  2. M protein clearance rate

    after each treatment of DFPP

    Time frame: 1hour

  3. creatinine clearance rate

    before each treatment of DFPP

    Time frame: 1hour

  4. creatinine clearance rate

    after each treatment of DFPP

    Time frame: 1hour

  5. albumin concentration

    before each treatment of DFPP

    Time frame: 1hour

  6. albumin concentration

    after each treatment of DFPP

    Time frame: 1hour

  7. serum-free light chain levels

    before each treatment of DFPP

    Time frame: 1hour

  8. serum-free light chain levels

    after each treatment of DFPP

    Time frame: 1hour

  9. blood urea nitrogen

    before each treatment of DFPP

    Time frame: 1hour

  10. blood urea nitrogen

    after each treatment of DFPP

    Time frame: 1hour

  11. Platelet concentrations

    before each treatment of DFPP

    Time frame: 1hour

  12. Platelet concentrations

    after each treatment of DFPP

    Time frame: 1hour

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Apr 2024, 35 months after the start.

Of 201 non-industry phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 99. This study's planned 35 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2021
First posted
Apr 8, 2021
StartActual
May 15, 2021
Primary completionEst.
Apr 30, 2024
CompletionEst.
Oct 31, 2024
Last update
Jul 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04836871
Lead sponsor
Fuling Zhou
Responsible party
Fuling Zhou (Head, Division of Hematology; Professor of Hematology; Doctoral advisor, Zhongnan Hospital) — Sponsor-investigator
First posted
Apr 8, 2021
Start date
May 15, 2021
Primary completion
Apr 30, 2024 (estimated)
Completion
Oct 31, 2024 (estimated)
Last update
Jul 13, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion